The eleventh report on survey of the adverse reaction to radiopharmaceuticals

This report deals with adverse reactions to radiopharmaceuticals occurring during the period from April 1, 1988 through March 31, 1989. Qestionnaires were sent to 1,110 facilities, and 748 (67.4%) responded. Twenty one cases of adverse reactions and 13 cases of drug defect were reported from a total of 24 facilities (3.2%), giving an annual occurrence of 2.6 cases and 1.6 cases, respectively, for 100,000 examinations. The incidence of adverse reactions was the highest for I-131-6β-iodomethyl-19-norcholesterol (n=254), followed by I-131 sodium iodide capsule (n=29), Tc-99m PMT injection (n=16), Tc-99m DTPA (n=12), I-131 sodium iodohippurate (n=12), Tc-99m pertechnetate (n=3), Tc-99m MDP injection (n=2), Tc-99m phytate (n=2), and Ga-67 citrate injection(n=one). Adverse reactions included reactions to the vagus nerves (n=7), allergic reactions (n=3), and others (n=11). Radiopharmaceuticals reported as drug defects were as follows: Tc-99m HMDP, Tc-99m MDP, Tc-99m PMT, Tc-99m pyrophosphate, and Tc-99m generator. (N.K.)